LIVZON PHARMA (01513) released its performance for the first three quarters, with a net profit attributable to shareholders of 1.754 billion yuan, a year-on-year increase of 4.86%.
Lizhu Pharmaceuticals (01513) releases its performance report for the first three quarters of 2025, with the group achieving a revenue of 9.116 billion yuan.
LIVZON PHARMA (01513) released its performance for the first three quarters of 2025, with the group achieving operating income of 9.116 billion yuan, a year-on-year increase of 0.38%; net profit attributable to company shareholders was 1.754 billion yuan, a year-on-year increase of 4.86%; basic earnings per share were 1.96 yuan.
Related Articles
Xinhua Winshare Publishing & Media (00811) will distribute a mid-year dividend of HK$0.208102 per share on December 23rd.
The stock price is undervalued! YIDU TECH (02158) signs total return swap to hedge against appreciation risk.
Q3 profits fall short of expectations + unclear growth narrative Tesla, Inc. (TSLA.US) receives mixed reviews from Wall Street after earnings.
Xinhua Winshare Publishing & Media (00811) will distribute a mid-year dividend of HK$0.208102 per share on December 23rd.
The stock price is undervalued! YIDU TECH (02158) signs total return swap to hedge against appreciation risk.
Q3 profits fall short of expectations + unclear growth narrative Tesla, Inc. (TSLA.US) receives mixed reviews from Wall Street after earnings.
RECOMMEND
Why European Automakers Are Opposing Dutch Sanctions
20/10/2025
Domestic Commercial Rockets Enter Batch Launch Era: Behind the Scenes a Sixfold Cost Gap and Reusability as the Key Breakthrough
20/10/2025
Multiple Positive Catalysts Lift Tech Stocks; UBS Elevates China Tech to Most Attractive, Citing AI as Core Rationale
20/10/2025
